Advancing Innovative
Oral Medicines
for people with inflammatory and
autoimmune diseases

Selectively modulating
key immune targets

To create differentiated medicines

Ventyx is a clinical-stage biopharmaceutical company focused on advancing novel oral therapies for patients living with autoimmune and inflammatory disorders. Our pipeline includes VTX958, a Phase 2 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases; VTX002, a Phase 2 S1P1 receptor modulator for the treatment of ulcerative colitis; VTX2735, a Phase 2 peripheral inhibitor of the NLRP3 inflammasome; and VTX3232, a Phase 1 CNS-penetrant inhibitor of the NLRP3 inflammasome.


Our approach allows us to streamline the discovery and development process.


Learn about our differentiated clinical-stage candidates and preclinical programs.


We are passionate about advancing novel therapies to improve the lives of patients.

Featured News